China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Read more about China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer Read more about Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer Read more about Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer
Zai Lab Announces Upcoming Presentations at December Investor Conferences Read more about Zai Lab Announces Upcoming Presentations at December Investor Conferences
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors Read more about Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP Read more about Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus Read more about Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia Read more about Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia
Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates Read more about Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China Read more about Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China